As I stood up to leave, the heavy oak door opened. Dr. Fletcher walked in, accompanied by a stern, incredibly wealthy-looking older man wearing a tailored Italian suit that radiated quiet, old money.
“Clara,” Dr. Fletcher said, his eyes dancing with excitement. “I’d like you to meet someone. This is Elias Thorne. He is the head of the Global Pharmaceutical Alliance, and coincidentally, Marcus Sterling’s chief corporate competitor.”
Mr. Thorne stepped forward, extending a calloused hand. “Dr. Hensley. I just watched your speech. It was the most brilliant defense of targeted molecular therapy I have heard in a decade.” He paused, his gaze turning intensely sharp. “I want to personally fund the construction of your private research laboratory. Unlimited capital. But I will only do it on one very specific condition.”
One year later.
The air in the Hensley Oncology Lab was perfectly climate-controlled, carrying the faint, clean scent of ozone and sterilized glass. Located in the newly constructed, sunlit wing of the university’s research center, it was widely considered the crown jewel of the institution.
I stood in the center of my pristine, state-of-the-art private laboratory. The walls were lined with millions of dollars of sequencing equipment, humming with quiet, obedient power. I wore a crisp, immaculate white lab coat, my name—Dr. Clara Hensley, MD/PhD, Director—embroidered in navy blue thread above my heart.
